NMUS - Nemus Bioscience, Inc. quick DD
$NMUS – at chart bottom – a serious, legitimate CBD research biotech company, in the right place, at the right time in American history. Fully SEC reporting and compliant, trading on the OTC, QB tier.
Nemus Bioscience, Inc. is a biopharmaceutical company that plans to develop and commercialize therapeutics from cannabinoids through an exclusive partnership with the University of Mississippi, the research hub of cannabinoid-based drugs, or CBDs, since 1965. The University of Mississippi ("UM") is federally permitted and licensed to cultivate cannabis for research and commercial purposes.
NOT a P&D – suitable for serious investors looking for 10x, 20x, 30x gains from current levels
From the 10-Q filed 11/10/16:
“As of November 8, 2016, there were 20,798,163 shares of the issuer's common stock, par value $0.001 per share, issued and outstanding.”
Small float, estimated 5 million shares. The share price moves easily and quickly, in both directions.
Top drugs in development:
NB1111 for the treatment of glaucoma.
NB1222 used for treating chemotherapy induced nausea and vomiting.
NB3111 for the treatment of methicillin-resistant Staphylococcus aureus.
NB2111 for use in treating chemotherapy induced peripheral neuropathy.
Nemus Bioscience, Inc. holds numerous patents relating to drug development and delivery systems that bypass the liver, which alters drug chemistry of medications taken orally.
Work on NB1111 has made Nemus Bioscience, Inc. a prime buyout candidate, as promising glaucoma drugs are highly sought in the $8 billion glaucoma industry worldwide, $2.3 billion in the U.S. alone.
Company website: www.nemusbioscience.com/home.html
